Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of TQH2722 injection in adults with moderate-to-severe atopic dermatitis
CTR20242940Phase 3Active
- Sponsor
- Nanjing Shunxin Pharmaceutical
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of TQH2722 in atopic dermatitis (AD), sponsored by Nanjing Shunxin Pharmaceutical. Started Oct 2024; status: active.
02
Drugs
TQH2722
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20242940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242940.